Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Medicare coverage determination cites publications from Oncocyte subsidary » 08:23
05/06/21
05/06
08:23
05/06/21
08:23
OCX

OncoCyte

$4.32 /

-0.13 (-2.92%)

Oncocyte announced that a…

Oncocyte announced that a pathway for future Medicare reimbursement coverage may have been created for TheraSure Transplant Monitor, a solid organ transplantation monitoring test developed by Oncocyte's subsidiary Chronix Biomedical. The Chronix monitoring test is intended to use a simple blood draw to monitor for rejection of transplanted organs. Palmetto, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services, issued a local coverage determination recognizing molecular testing for solid organ allograft rejection as a category of tests eligible for Medicare reimbursement. This policy extends coverage to any method providing donor derived cell-free DNA values with proven analytical performance. The decision establishes a simplified and accelerated pathway for Medicare reimbursement coverage that Oncocyte's new subsidiary Chronix may follow for its patented solid tumor organ transplant rejection monitoring technology. The coverage policy for transplant rejection monitoring, Molecular Testing for Solid Organ Allograft Rejection, cites three peer reviewed publications on the performance of the Chronix test in solid organ transplant monitoring, and establishes a pricing parameter of $2,700-$2,800 per test depending on the organ transplanted. Oncocyte estimates that total revenues could range from $40,000-$50,000 per patient over a two-to-three year timeframe assuming current transplant monitoring guidelines are followed. The Chronix TheraSure Transplant Monitor test has been validated in clinical cohorts after kidney, heart and liver transplantation. It is also the only patented assay available for dd-cfDNA that reveals absolute cfDNA concentrations in addition to percentage values. Peer reviewed journals and numerous studies have established that absolute concentration data are superior to percentage value data in rejection detection1 in kidney and eliminate a systematic bias seen in competing technologies used to test organ rejection in patients later than one year after transplant.

ShowHide Related Items >><<
OCX OncoCyte
$4.32 /

-0.13 (-2.92%)

OCX OncoCyte
$4.32 /

-0.13 (-2.92%)

04/12/21 Lake Street
AACR data strengthens 'pan-cancer credentials' for OncoCyte, says Lake Street
04/12/21 Piper Sandler
OncoCyte remains a top pick small-cap pick at Piper Sandler
03/30/21 Piper Sandler
OncoCyte called 'top small-cap pick' at Piper Sandler
03/17/21
Fly Intel: Top five analyst initiations
OCX OncoCyte
$4.32 /

-0.13 (-2.92%)

  • 05
    Feb
OCX OncoCyte
$4.32 /

-0.13 (-2.92%)

Conference/Events
OncoCyte to host conference call » 11:25
04/19/21
04/19
11:25
04/19/21
11:25
OCX

OncoCyte

$4.45 /

-0.37 (-7.68%)

Management hosts KOLs…

Management hosts KOLs Drs. Gandara & Parikh, of UC Davis Comprehensive Cancer Center to discuss novel Biomarkers in identifying appropriate responders to immune checkpoint inhibitors on a conference call to be held on April 19 at 11:30 am. Webcast Link

ShowHide Related Items >><<
OCX OncoCyte
$4.45 /

-0.37 (-7.68%)

OCX OncoCyte
$4.45 /

-0.37 (-7.68%)

04/12/21 Lake Street
AACR data strengthens 'pan-cancer credentials' for OncoCyte, says Lake Street
04/12/21 Piper Sandler
OncoCyte remains a top pick small-cap pick at Piper Sandler
03/30/21 Piper Sandler
OncoCyte called 'top small-cap pick' at Piper Sandler
03/17/21
Fly Intel: Top five analyst initiations
OCX OncoCyte
$4.45 /

-0.37 (-7.68%)

  • 05
    Feb
OCX OncoCyte
$4.45 /

-0.37 (-7.68%)

Conference/Events
OncoCyte to host conference call » 09:54
04/19/21
04/19
09:54
04/19/21
09:54
OCX

OncoCyte

$4.71 /

-0.11 (-2.28%)

Management hosts KOLs…

Management hosts KOLs Drs. Gandara & Parikh, of UC Davis Comprehensive Cancer Center to discuss novel Biomarkers in identifying appropriate responders to immune checkpoint inhibitors on a conference call to be held on April 19 at 11:30 am. Webcast Link

ShowHide Related Items >><<
OCX OncoCyte
$4.71 /

-0.11 (-2.28%)

OCX OncoCyte
$4.71 /

-0.11 (-2.28%)

04/12/21 Lake Street
AACR data strengthens 'pan-cancer credentials' for OncoCyte, says Lake Street
04/12/21 Piper Sandler
OncoCyte remains a top pick small-cap pick at Piper Sandler
03/30/21 Piper Sandler
OncoCyte called 'top small-cap pick' at Piper Sandler
03/17/21
Fly Intel: Top five analyst initiations
OCX OncoCyte
$4.71 /

-0.11 (-2.28%)

  • 05
    Feb
OCX OncoCyte
$4.71 /

-0.11 (-2.28%)

Hot Stocks
OncoCyte closes acquisition of Chronix Biomedical » 08:05
04/19/21
04/19
08:05
04/19/21
08:05
OCX

OncoCyte

$4.82 /

-0.26 (-5.12%)

Oncocyte Corporation has…

Oncocyte Corporation has completed its acquisition of Chronix Biomedical. The acquisition includes the intellectual property and technology for Chronix's TheraSure-Copy Number Instability Monitor test for immune therapy monitoring. The Chronix CNI test is a patented, novel blood-based test that is differentiated from current methods because it requires no upfront tumor tissue sample. With the acquisition, Oncocyte also gains the organ transplant technology and the associated patent portfolio developed by Chronix. The addition of the CNI test to Oncocyte's portfolio of diagnostic products marks the Company's entry into blood-based immune-therapy monitoring, a market that is estimated at $3 billion in the United States alone. Ownership of Chronix's intellectual property portfolio helps establish the foundation for Oncocyte to potentially build additional applications to address an estimated $6 billion U.S. recurrence monitoring market. Further, as approximately 40%-60% of patients fail to see a sustained response to immune checkpoint inhibitors, it is estimated that by 2025, more than $60 billion a year could be misspent on treatments that may never benefit patients. The acquisition, which includes Chronix's lab in Germany and its EU-based development and business team, establishes a footprint for the continued development and potential commercial launch of Oncocyte's proprietary tests in the European market. The Company expects to launch the CNI test as a pharma service in Europe from Germany by the end of the current quarter. After the tech transfer to its U.S. facilities, Oncocyte plans to launch the test for research use only in domestic immune therapy clinical trials during the fourth quarter of this year. The anticipated first indication for use will be in lung cancer, followed by expansion to other cancer types. Further, as the path to reimbursement is already established, Oncocyte plans to demonstrate the comparability of the CNI test to existing reimbursed tests. Also included in the acquisition are tests and a patent estate for the use of digital PCR to detect transplant rejection in recipients as well as enabling the absolute amount of tumor or donor cell-free DNA, which eliminates the influence of changes in cell-free DNA caused by unrelated reasons making the technique more specific for monitoring. The Company plans to explore the use of the patented methodologies and combine with digital PCR for development of super-sensitive detection of tumor-derived DNA in blood to monitor for long-term recurrence as well as explore licensing this technology and patent estate for transplant to potential partners.

ShowHide Related Items >><<
OCX OncoCyte
$4.82 /

-0.26 (-5.12%)

OCX OncoCyte
$4.82 /

-0.26 (-5.12%)

04/12/21 Lake Street
AACR data strengthens 'pan-cancer credentials' for OncoCyte, says Lake Street
04/12/21 Piper Sandler
OncoCyte remains a top pick small-cap pick at Piper Sandler
03/30/21 Piper Sandler
OncoCyte called 'top small-cap pick' at Piper Sandler
03/17/21
Fly Intel: Top five analyst initiations
OCX OncoCyte
$4.82 /

-0.26 (-5.12%)

  • 05
    Feb
OCX OncoCyte
$4.82 /

-0.26 (-5.12%)

Over a month ago
Recommendations
AACR data strengthens 'pan-cancer credentials' for OncoCyte, says Lake Street » 08:59
04/12/21
04/12
08:59
04/12/21
08:59
OCX

OncoCyte

$5.33 /

+0.005 (+0.09%)

Lake Street analyst…

Lake Street analyst Thomas Flaten said OncoCyte's presentation of new DetermaIO data in urothelial cancer at the ongoing American Association for Cancer Research, or AACR, meeting strengthens the test's "pan-cancer credentials," noting that this is the third tumor type for which DetermaIO has demonstrated success. Flaten keeps a Buy rating and $11 price target on OncoCyte shares.

ShowHide Related Items >><<
OCX OncoCyte
$5.33 /

+0.005 (+0.09%)

OCX OncoCyte
$5.33 /

+0.005 (+0.09%)

04/12/21 Piper Sandler
OncoCyte remains a top pick small-cap pick at Piper Sandler
03/30/21 Piper Sandler
OncoCyte called 'top small-cap pick' at Piper Sandler
03/17/21
Fly Intel: Top five analyst initiations
03/17/21 Needham
OncoCyte assumed with a Buy at Needham
OCX OncoCyte
$5.33 /

+0.005 (+0.09%)

  • 05
    Feb
OCX OncoCyte
$5.33 /

+0.005 (+0.09%)

Recommendations
OncoCyte remains a top pick small-cap pick at Piper Sandler » 05:03
04/12/21
04/12
05:03
04/12/21
05:03
OCX

OncoCyte

$5.33 /

+0.005 (+0.09%)

Piper Sandler analyst…

Piper Sandler analyst Steven Mah says OncoCyte remains his top small-cap pick after the company presented two new DetermaIO studies in bladder cancer. DetermaIO achieved its primary-endpoint showing significant correlation between DetermaIO status and two-year overall survival to atezolizumab in metastatic bladder cancer, Mah tells investors in a research note. The analyst believes there is a "significant" pharma partnership opportunity for DetermaIO and sees additional catalysts in 2021 He reiterates an Overweight rating on OncoCyte with a $7 price target.

ShowHide Related Items >><<
OCX OncoCyte
$5.33 /

+0.005 (+0.09%)

OCX OncoCyte
$5.33 /

+0.005 (+0.09%)

03/30/21 Piper Sandler
OncoCyte called 'top small-cap pick' at Piper Sandler
03/17/21
Fly Intel: Top five analyst initiations
03/17/21 Needham
OncoCyte assumed with a Buy at Needham
03/17/21 Benchmark
OncoCyte price target raised to $11 from $6 at Benchmark
OCX OncoCyte
$5.33 /

+0.005 (+0.09%)

  • 05
    Feb
OCX OncoCyte
$5.33 /

+0.005 (+0.09%)

Hot Stocks
OncoCyte presents new data on potential for pan-cancer utility of DetermaIO » 17:50
04/11/21
04/11
17:50
04/11/21
17:50
OCX

OncoCyte

$5.33 /

+0.005 (+0.09%)

Oncocyte Corporation…

Oncocyte Corporation presented new data at the American Association for Cancer Research Annual Meeting 2021. The presentations featured studies of Oncocyte's novel predictor of immunotherapy response, DetermaIO, demonstrating test performance in bladder cancer, now the third cancer type, suggesting potential applicability across multiple cancer types. DetermaIO has previously been shown to predict immunotherapy response in lung and breast cancers in studies using four different approved checkpoint inhibitors - Keytruda, Opdivo, Tecentriq and Imfinzi. At the conference, Oncocyte debuted data in bladder cancer in two studies, including one highlighted in a podium presentation. The poster, titled "Pathway modeling to translate the 27-gene immuno-oncology algorithm into bladder cancer," detailed the application of the DetermaIO test and proprietary algorithm for the classification of metastatic bladder cancer. This study demonstrated a novel approach of looking at the tumor microenvironment at a genomic scale, as well as validating the use of the test, without any further modification, in bladder cancer to assess its association with Immune Checkpoint Inhibitor response. During the podium presentation, titled "Validation of a 27-gene immuno-oncology algorithm in metastatic urothelial carcinoma treated with an immune checkpoint inhibitor," the results of a prospectively defined analysis of clinical trial results from the IMvigor210 study of atezolizumab, an immunotherapy used to treat bladder and other cancers, was revealed. Oncocyte's DetermaIO test measures the expression of 27 genes and combines them with a proprietary algorithm to classify the entire tumor immune microenvironment present in solid tumor biopsy samples. The company's previously released data demonstrated that the combination of measuring the "hot" inflammatory immune response combined with the "cold" immune repressive signature coming from the wound response in tumor specimens, is strongly associated with response to ICIs in lung and breast cancer.

ShowHide Related Items >><<
OCX OncoCyte
$5.33 /

+0.005 (+0.09%)

OCX OncoCyte
$5.33 /

+0.005 (+0.09%)

03/30/21 Piper Sandler
OncoCyte called 'top small-cap pick' at Piper Sandler
03/17/21
Fly Intel: Top five analyst initiations
03/17/21 Needham
OncoCyte assumed with a Buy at Needham
03/17/21 Benchmark
OncoCyte price target raised to $11 from $6 at Benchmark
OCX OncoCyte
$5.33 /

+0.005 (+0.09%)

  • 05
    Feb
OCX OncoCyte
$5.33 /

+0.005 (+0.09%)

Recommendations
OncoCyte called 'top small-cap pick' at Piper Sandler » 05:30
03/30/21
03/30
05:30
03/30/21
05:30
OCX

OncoCyte

$4.41 /

-0.3 (-6.37%)

After hosting meetings…

After hosting meetings with management, Piper Sandler analyst Steven Mah has increased confidence in OncoCyte's continued global expansion and its goal to be the "one-stop shop" across the continuum of oncology testing. DetermaIO is the story now since its opportunity of $5B globally is much bigger than DetermaRx, Mah tells investors in a research note. The analyst calls OncoCyte a "top small-cap pick with multiple upcoming catalysts." He keeps an Overweight rating on the shares with a $7 price target.

ShowHide Related Items >><<
OCX OncoCyte
$4.41 /

-0.3 (-6.37%)

OCX OncoCyte
$4.41 /

-0.3 (-6.37%)

03/17/21
Fly Intel: Top five analyst initiations
03/17/21 Needham
OncoCyte assumed with a Buy at Needham
03/17/21 Benchmark
OncoCyte price target raised to $11 from $6 at Benchmark
02/10/21 Piper Sandler
OncoCyte price target raised to $7 from $4 at Piper Sandler
OCX OncoCyte
$4.41 /

-0.3 (-6.37%)

  • 05
    Feb
OCX OncoCyte
$4.41 /

-0.3 (-6.37%)

Initiation
Fly Intel: Top five analyst initiations » 09:57
03/17/21
03/17
09:57
03/17/21
09:57
XM

Qualtrics

$35.00 /

-0.95 (-2.64%)

, AEVA

Aeva Technologies

$15.15 /

+0.11 (+0.73%)

, WWW

Wolverine World Wide

$41.13 /

+0.35 (+0.86%)

, OCX

OncoCyte

$4.85 /

-0.27 (-5.27%)

, DKS

Dick's Sporting

$78.06 /

+1.46 (+1.91%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Qualtrics (XM) initiated with a Hold at HSBC. 2. Aeva Technologies (AEVA) initiated with a Buy at Craig-Hallum. 3. Wolverine World Wide (WWW) initiated with a Buy at Williams Trading. 4. OncoCyte (OCX) assumed with a Buy at Needham. 5. Dick's Sporting (DKS) initiated with a Buy at Williams Trading. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
XM Qualtrics
$35.00 /

-0.95 (-2.64%)

OCX OncoCyte
$4.85 /

-0.27 (-5.27%)

DKS Dick's Sporting
$78.06 /

+1.46 (+1.91%)

AEVA Aeva Technologies
$15.15 /

+0.11 (+0.73%)

XM Qualtrics
$35.00 /

-0.95 (-2.64%)

03/17/21 HSBC
Qualtrics initiated with a Hold at HSBC
03/17/21 HSBC
Qualtrics initiated with a Hold at HSBC
03/11/21 Deutsche Bank
Qualtrics price target lowered to $41 from $56 at Deutsche Bank
03/11/21 Loop Capital
Qualtrics price target lowered to $35 from $45 at Loop Capital
AEVA Aeva Technologies
$15.15 /

+0.11 (+0.73%)

03/17/21 Craig-Hallum
Aeva Technologies initiated with a Buy at Craig-Hallum
03/17/21 Roth Capital
Aeva Technologies initiated with a Buy at Roth Capital
WWW Wolverine World Wide
$41.13 /

+0.35 (+0.86%)

03/17/21 Williams Capital
Williams Trading starts Wolverine World Wide at Buy with $47 price target
03/17/21 Williams Capital
Wolverine World Wide initiated with a Buy at Williams Trading
02/26/21 Baird
Wolverine World Wide price target raised to $42 from $34 at Baird
02/22/21 Pivotal Research
Wolverine World Wide price target raised to $40 from $33 at Pivotal Research
OCX OncoCyte
$4.85 /

-0.27 (-5.27%)

03/17/21 Needham
OncoCyte assumed with a Buy at Needham
03/17/21 Benchmark
OncoCyte price target raised to $11 from $6 at Benchmark
02/10/21 Piper Sandler
OncoCyte price target raised to $7 from $4 at Piper Sandler
01/05/21 Benchmark
GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021
DKS Dick's Sporting
$78.06 /

+1.46 (+1.91%)

03/17/21 Williams Capital
Williams Trading starts Dick's Sporting at Buy with $100 price target
03/17/21 Williams Capital
Dick's Sporting initiated with a Buy at Williams Trading
03/10/21 RBC Capital
Dick's Sporting price target lowered to $74 from $78 at RBC Capital
03/10/21 Evercore ISI
Dick's Sporting price target raised to $100 from $75 at Evercore ISI
XM Qualtrics
$35.00 /

-0.95 (-2.64%)

WWW Wolverine World Wide
$41.13 /

+0.35 (+0.86%)

OCX OncoCyte
$4.85 /

-0.27 (-5.27%)

DKS Dick's Sporting
$78.06 /

+1.46 (+1.91%)

  • 05
    Feb
  • 28
    Jan
XM Qualtrics
$35.00 /

-0.95 (-2.64%)

XM Qualtrics
$35.00 /

-0.95 (-2.64%)

OCX OncoCyte
$4.85 /

-0.27 (-5.27%)

DKS Dick's Sporting
$78.06 /

+1.46 (+1.91%)

XM Qualtrics
$35.00 /

-0.95 (-2.64%)

DKS Dick's Sporting
$78.06 /

+1.46 (+1.91%)

AEVA Aeva Technologies
$15.15 /

+0.11 (+0.73%)

Initiation
OncoCyte assumed with a Buy at Needham » 08:03
03/17/21
03/17
08:03
03/17/21
08:03
OCX

OncoCyte

$5.11 /

+0.15 (+3.02%)

Needham analyst Mike…

Needham analyst Mike Matson assumed coverage of OncoCyte with a Buy rating and $8 price target. The company missed on Q4 revenue due to the impact of COVID-19 resurgence with a 9.4% sequential decline, though it continues to make progress with the launch of DetermaRx, the analyst tells investors in a research note. Matson believes that OncoCyte has strong potential for long-term revenue growth associated with the commercialization of an expanding portfolio of advanced diagnostic tests focused on cancer.

ShowHide Related Items >><<
OCX OncoCyte
$5.11 /

+0.15 (+3.02%)

OCX OncoCyte
$5.11 /

+0.15 (+3.02%)

03/17/21 Benchmark
OncoCyte price target raised to $11 from $6 at Benchmark
02/10/21 Piper Sandler
OncoCyte price target raised to $7 from $4 at Piper Sandler
01/05/21 Benchmark
GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021
12/17/20 BTIG
BTIG positive on select healthcare diagnostic/tools names as '2021 Top Picks'
OCX OncoCyte
$5.11 /

+0.15 (+3.02%)

  • 05
    Feb
OCX OncoCyte
$5.11 /

+0.15 (+3.02%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.